R&D | November 25, 2025
Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025
Jaypirca is making waves in the fight against B-cell malignancies
Jaypirca is making waves in the fight against B-cell malignancies
Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Subscribe To Our Newsletter & Stay Updated
